Molecular therapy in pancreatic adenocarcinoma (Q35874708)

10 August 2017

1 reference

title

Molecular therapy in pancreatic adenocarcinoma (English)

1 reference

10 August 2017

1 reference

Mary J MacKenzie

1

1 reference

10 August 2017

1 September 2004

1 reference

Lancet Oncology Commission

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

9

1 reference

10 August 2017

541-549

1 reference

10 August 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

New perspectives in the management of pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Combined modality therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

The molecular genetics of pancreatic ductal carcinoma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Current status of gene therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Gene therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Adenoviral-mediated suicide gene therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Replication-selective microbiological agents: fighting cancer with targeted germ warfare

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Apoptosis in cancer--implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Strategies for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

1 reference

7 January 2021

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Angiogenesis and antiangiogenic strategies in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Immunotherapy for pancreatic cancer: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

The epidermal growth factor receptor in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Exploiting molecular targets in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901565-7

7 January 2021

10.1016/S1470-2045(04)01565-7

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15337483